Trials / Terminated
TerminatedNCT01912404
Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Corticosteroid Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Conatus Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study is to test if taking a study drug called emricasan (also known as IDN-6556 and PF-03491390) will affect overall patient survival after one month of treatment.
Detailed description
The study will also see if overall patient survival is affected at 6 months, and if the study drug improves liver function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDN-6556 | 25 mg BID for 28 days |
| DRUG | Placebo | Placebo controlled |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2013-07-31
- Last updated
- 2016-11-04
- Results posted
- 2016-11-04
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01912404. Inclusion in this directory is not an endorsement.